Trial Profile
ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary) ; Perindopril (Primary) ; Perindopril/amlodipine (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms ACCESS
- 02 Jun 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 13 Aug 2013 Treatment table added.
- 20 Jul 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.